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Abstract
Background: Burkholderia cenocepacia is a Gram-negative, opportunistic pathogen that is a cause of morbidity and
mortality in patients with cystic fibrosis (CF). Research efforts over the past few decades contributed to our
understanding of these infections by identifying virulence factors. However, little is known about how this
pathogen adapts to the harsh environment found inside the CF airways, which is characterized by a unique mucus
containing high concentrations of inflammatory markers. The current study developed a novel model to further
investigate this phenomenon.
Results: Monolayers of human A549 lung carcinoma cells (HLCCs) were exposed to a mixture of artificial CF
sputum medium (ASMDM) in tissue culture growth medium, and subsequently infected with B. cenocepacia K56-2
for 24 h. The data showed that this model supported B. cenocepacia growth. In addition, consistent with similar
studies using current models such as CF airway tissue samples, HLCC viability was reduced by more than 70 %
when grown in 60 % ASMDM and infected with B. cenocepacia compared to mock-infected controls and medium
alone. Furthermore, the amount of B. cenocepacia cells associated with the HLCC monolayer was more than 10
times greater in 60 % ASMDM when compared to medium controls.
Conclusions: These findings suggest that HLCC monolayers in 60 % ASMDM serve as a valid alternative to study B.
cenocepacia infections in patients with CF, and possibly other chronic diseases of the airways. Furthermore, the
results obtained in this study suggest an important role for CF sputum in B. cenocepacia pathogenesis.
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Background
Mucus plays an important protective role in our host de-
fenses by trapping inhaled particles such as pathogens
that are subsequently transported out of the airways by
ciliated epithelial cells. For this mucociliary clearance to
work effectively, the cilia must constantly be moving in
the thin, moist layer of mucus. Some diseases such as
cystic fibrosis (CF) and primary ciliary dyskinesia (PCD)
impair this clearance mechanism resulting in chronic
lung infections. More specifically, mutations in the cystic
fibrosis conductance regulator cause a disruption in the
transfer of Cl- across the cell membrane. Consequently,
the mucus layer becomes thick and dehydrated prevent-
ing the successful removal of the particles. PCD patients
have defective cilia structure causing the cilia to beat ab-
normally. Previous research indicated that there exists
striking similarities in terms of mucus biophysical and
chemical properties between PCD and CF sputum [1–3].
In addition to impaired mucociliary clearance, both dis-
eases have a neutrophil-dominated inflammation in the air-
ways. These conditions are challenging for many bacteria,
however highly adaptable pathogens such as Pseudomonas
aeruginosa, Staphylococcus aureus, Haemophilus influenza
survive in the CF and PCD airways (see review [2, 4]) and
B. cenocepacia thrives in the CF airways (see review [4–6]).
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Burkholderia cenocepacia is a member of the Burkhol-
deria cepacia Complex (BCC) that comprises 18 species
that are Gram-negative opportunistic pathogens [7]. It is
innately resistant to a wide array of antibiotics including
aminoglycosides, quinolones, and β-lactams [8], (see re-
view [4]). It possesses a variety of virulence factors such
as cable pili, biofilm formation, degradative enzymes (see
review [9]), (see review [10]), and it is transmitted from
person-to-person [11] and from the environment [12].
While the majority of CF patients infected with B. ceno-
cepacia experiences a gradual deterioration of lung func-
tion [6, 8], nearly 20 % of infected CF patients
experience “cepacia syndrome”. This is a fatal case of
necrotizing pneumonia sometimes associated with septi-
cemia that may lead to death within one year [6, 13]. Be-
cause of these attributes, this pathogen poses a serious
threat to CF patients.
Over the past decade progress has led to a greater un-
derstanding of how B. cenocepacia causes disease in CF
patients (see review [9]). However, because there is still
no definite cure, further research is needed, on how this
pathogen adapts to the harsh CF airways as such infor-
mation could lead to new forms of treatment. Unfortu-
nately, for investigative purposes, it can be very difficult
to acquire sputum or tissue samples from CF patients,
and there exists a need for an alternative, readily avail-
able method to investigate B. cenocepacia infections in
CF patients and patients with similar chronic diseases of
the airways.
Fung et al. [14] developed an artificial sputum medium
(ASMDM) that approximates the sputum found in CF
patients in terms of components, concentrations of the
components, and physical properties. In their study, they
found that Pseudomonas aeruginosa, another opportun-
istic pathogen commonly found in CF airways (see re-
view [4, 15]) grew normally and deeply invaded the
ASMDM, suggesting that ASMDM mimicked the CF
lower airway mucus well [14]. In addition, the fact that
ASMDM seems to be a good substitute for CF mucus
and a good growth medium for P. aeruginosa suggests
that ASMDM would be a suitable growth medium for B.
cenocepacia.
Nevertheless, using ASMDM by itself is not sufficient to
simulate the in vivo conditions in the lungs of CF patients,
as this model lacks live host cells that can respond to a B.
cenocepacia infection. Saijan et al. investigated B. cenoce-
pacia infections in the presence of well-differentiated
human CF cells and in non-CF human lung epithelial cells
[16]. They found that infected CF cells contained signifi-
cantly more bacteria in both the mucosal layer and inside
the cell layer when compared to infected non-CF cells
[16]. This study showed that B. cenocepacia penetrated
the mucosal and cellular layers which is comparable to its
activity in the CF airways.
Our study investigated the accuracy and effectiveness
of ASMDM on a monolayer of human A549 lung
carcinoma cells, as a model to investigate B. cenocepacia
infections in CF and PCD patients. Although the litera-
ture indicates that B. cenocepacia has never been iso-
lated from PCD airways, similarities in mucus
biophysical and chemical properties and bacterial flora
between the sputa seem striking enough to suspect that
B. cenocepacia may be able to colonize PCD airways as
well. Therefore, this model could be a valid alternative
to investigate B. cenocepacia infections in CF patients,
and it might be used to investigate B. cenocepacia or
other infections in PCD patients as well.
Methods
Cell line and propagation
Human A549 lung carcinoma cells (HLCCs) (American
Type Culture Collection, Manassas, VA) were main-
tained in 1 mL aliquots at −80 °C. Prior to experimental
use, 1 mL HLCCs was thawed in a 37 °C water bath,
transferred to a Falcon T25 vial (Fisher Scientific, Han-
over Park, IL) containing 5 mL Ham’s F-12 complete
medium (American Type Culture Collection), and incu-
bated at 37 °C (7 % CO2). At confluency, HLCCs were
detached from the flask surface with 2 mL 1X trypsin-
EDTA (Mediatech, Inc., Manassas VA), and added to
10 mL Ham’s F-12 complete medium in a Falcon T75
vial (Fisher Scientific, Hanover Park, IL).
Bacterial strain and culture conditions
Burkholderia cenocepacia K56-2 [17] was grown in
10 mL Luria-Bertani broth. Cultures were incubated for
24 h at 37 °C with shaking (150 rpm).
Preparation of artificial sputum medium (ASMDM)
ASMDM was prepared in 30 mL aliquots as described
by Fung et al. [14]. Porcine stomach mucin (Sigma-Al-
drich, St. Louis, MO), DNA from salmon testes (Sigma-
Aldrich, St. Louis, MO), potassium chloride (Fisher Sci-
entific, Hanover Park, IL), sodium chloride (Fisher Sci-
entific, Hanover Park, IL), diethylene triamine
pentaacetic acid (Fluka Analytical, St. Louis, MO), casa-
mino acids (Acros, Hanover Park, IL), and bovine serum
albumin (Sigma-Aldrich, St. Louis, MO) were dis-
solved in 25 mL sterile dH2O (final concentrations:
10 mg/mL, 1.4 mg/mL, 2.2 mg/mL, 5 mg/mL,
5.9 mg/mL, 5 mg/mL, and 10 mg/mL, respectively).
Egg yolk emulsion (0.15 mL) (Becton Dickinson) and
the antibiotics ampicillin (1 ug/mL; (Fisher Scientific,
Hanover Park, IL) and penicillin (1 ug/mL; Sigma-
Aldrich, St. Louis, MO) were added to revent
contamination. Tetracycline was omitted because B.
cenocepacia is sensitive to this antibiotic [18]. The
suspension was stirred for 5 min at room temperature
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to dissolve the DNA and mucin. The pH was adjusted
to 6.5, and sterile dH2O was added to 30 mL
ASMDM was stored at 4 °C, but warmed to 37 °C
before addition to cells.
Determination of optimal concentration of ASMDM for
HLCCs and B. cenocepacia
HLCCs (0.5 mL) were added to gas-permeable 24-well
plates (Coy Laboratory Products, Inc., Grass Lake, MI)
at 4x105 cells/mL. The plates were incubated at 37 °C
(7 % CO2) for 24 h to form a monolayer. The medium
was discarded, cells were washed once with 0.5 mL 1X
HBSS (Mediatech, Manassas, VA), and then exposed to
either 0.5 mL Ham’s F-12 complete medium, ASMDM
suspended in Ham’s F-12 complete medium at varying
concentrations (20 %, 40 %, 60 %, or 80 %), or 100 %
ASMDM. Two wells were not manipulated (i.e. not
washed, and medium not replaced), and were designated
as the T24 control. Plates were then incubated at 37 °C
(7 % CO2). After 24 h, the supernatant was removed
from all wells (including T24 wells), washed with 0.5 mL
1X HBSS, and then washed with 0.5 mL 1X trypsin-EDTA.
Cells were detached from the well surface with 0.5 mL 1X
trypsin-EDTA at 37 °C (7 % CO2) for 10 min. The cell
density (cells/mL) was determined. The cell viability (% live
cells) was measured with Trypan blue staining.
To determine the optimal concentration of ASMDM
for B. cenocepacia viability, 1 mL of the overnight cul-
ture was centrifuged at 14,000 rpm for 2 min, washed in
1 mL saline, and then suspended in 1 mL saline. This
suspension (10 μL) was added to non-gas permeable 24-
well plates (Fisher Scientific, Hanover Park, IL) contain-
ing either 0.5 mL Ham’s F-12 complete medium,
ASMDM suspended in Ham’s F-12 complete medium at
varying concentrations (20 %, 40 %, 60 %, or 80 %), or
100 % ASMDM. The plate was incubated at 37 °C (7 %
CO2). After 24 h, CFU/mL per well was determined via
viable cell plating. The CFU/mL of the saline suspension
was determined via viable cell plating; this is the T0
control.
Assessment of the effects of B. cenocepacia on HLCCs
with 60 % ASMDM
HLCCs suspended in Ham’s F-12 complete medium
(0.5 ml) was added to a gas-permeable 24-well plate at a
density of 3 × 105 cells/mL and incubated at 37 °C (7 %
CO2) for approximately 24 h until confluent. The
medium was discarded. Cells were washed once with
0.5 mL 1X HBSS, and then exposed to 0.5 mL medium
or 60 % ASMDM in Ham’s F-12 complete medium.
Wells without HLCCs were filled with 0.5 mL medium
or 100 % ASMDM. Wells were either treated with 10 μL
of B. cenocepacia in saline at MOI 0.3-5 or mock-
infected with saline. Two wells were not manipulated for
the duration of the experiment to assess the cell density
(T24 controls). The plates were incubated at 37 °C (7 %
CO2). After 24 h, damage to the monolayer was assessed
with an inverted Zeiss axiovert 40 CFL microscope (W.
Nuhsbaum, Inc., McHenry, IL), a microscope-mounted
camera (AmScope, Irvine, CA), and Leica LAS v4.6.2.
software. Damage was defined as the presence of gaps in
the monolayer. To assess the cell density and viability of
HLCCs, half the wells were treated as follows. The
remaining supernatant was discarded, cells were rinsed
twice with 0.5 mL 1X HBSS, and once with 0.5 mL
1X trypsin-EDTA. Wells were then filled with another
0.5 mL 1X trypsin-EDTA and stored at 37 °C (7 %
CO2) for 10 min. The cell density and viability were
determined.
The remaining wells were used to measure bacterial
density. To quantify the bacteria in the supernatant,
0.2 ml was plated for cell viability. To quantify internal
and adherent bacteria, the wells were treated as follows.
The remaining supernatant was removed, cells were
washed twice with 0.5 mL 1X HBSS, and once with
0.5 mL sterile dH2O. Wells were then filled with 1 mL
sterile dH2O and incubated at 37 °C (7 % CO2) for one
hour to degrade the monolayer and lyse the HLCCs.
Samples (0.2 mL) were removed for viable cell plating.
Results
ASMDM concentration for optimal HLCC viability
We used ASMDM to simulate the CF mucous compos-
ition and viscosity [14], gas-permeable plates to allow
for appropriate gas exchange, and human A549 lung car-
cinoma cells (HLCC) to proxy for CF epithelial cells be-
cause studies showed that Burkholderia invades this cell
line [19, 20]. First, we determined the concentration of
ASMDM necessary to maintain HLCC density. Our re-
sults showed that the average cell density ratio in 0 %
ASMDM was greater compared to the other concentra-
tions. However, the differences were not significantly dif-
ferent (oneway ANOVA, p = 0.07) (Fig. 1) indicating that
the cell density was not influenced by the ASMDM con-
centration. Next, we measured the HLCC viability.
When the cells were exposed to 0 through 60 %
ASMDM the cell viability was high (around 90 %), but
decreased to 75 % in 80 % ASMDM and 24 % in 100 %
ASMDM (Fig. 2). The differences in cell viability be-
tween the different concentrations of ASMDM were sig-
nificantly different (oneway ANOVA, p < 0.0001). A
Tukey-HSD post-hoc test indicated that the mean cell
viability in 100 % ASMDM is significantly different com-
pared to 0 through 80 % ASMDM (p < 0.0001 for all),
and that the mean cell viability in 80 % ASMDM is
significantly different compared to 0 or 20 %
ASMDM (p = 0.0336 and p = 0.0404, respectively).
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The effect of ASMDM on the viability of B. cenocepacia
To determine whether ASMDM affected B. cenocepacia
growth, 10 μL of bacterial suspension (approximately 5
× 108 CFU/mL) was added to non-gas-permeable plates
containing ASMDM. B. cenocepacia grew in all concen-
trations of ASMDM, but grew better (>100-fold) in wells
containing at least 20 % ASMDM than in Ham’s F-12
complete medium alone. A Tukey-HSD post hoc test
showed that 0 % is significantly different from the 60
and 80 % ASMDM (oneway ANOVA, p = 0.03) (Fig. 3).
These results suggested that B. cenocepacia grew well in
at least 20 % ASMDM (Fig. 3). Therefore, in combin-
ation with the HLCC viability and cell density data, we
used 60 % ASMDM for our model.
The effect of B. cenocepacia on HLCCs in 60 % ASMDM
We measured the effect of infection by first examining
the integrity of the monolayer. Mock-infected HLCC
monolayers in Ham’s F-12 complete medium or 60 %
ASMDM showed no signs of monolayer damage (Fig. 4a
Fig. 1 Effect of ASMDM on the density of human lung carcinoma cells A549 (HLCCs). Confluent HLCCs grown in gas permeable 24-well plates were
exposed to varying concentrations of ASMDM in Ham’s F-12 complete medium. After 24 h, the cell density (cells/mL) of HLCCs was compared to the cell
density of T24 control HLCCs. T24 control consisted of HLCC monolayers in Ham’s F-12 complete medium that were not manipulated (i.e. not washed, and
medium was not replaced) for the duration of the experiment. There are no statistically significant differences between any of the different combinations
(oneway ANOVA, p= 0.07). Values are averages from four independent experiments each with duplicate wells. Bars show standard deviation
A CBA A/B A/B
Fig. 2 The effect of ASMDM on the viability of HLCCs. Confluent HLCCs grown in gas permeable 24-well plates were exposed to varying
concentrations of ASMDM in Ham’s F-12 complete medium. After 24 h, mean viability was determined using Trypan blue staining. There
are statistically significant differences in mean cell viability between the different combinations (ANOVA, p < 0.0001). A Tukey-HSD post-hoc
test indicated that the mean cell viability in 100 % ASMDM is statistically different from the 0, 20, 40, 60, or 80 % ASMDM (p < 0.0001 for all), and that
the mean cell viability in 80 % ASMDM is statistically different than the 0 or 20 % ASMDM (p = 0.0336 and p = 0.0404, respectively). Values are averages
of four independent experiments with duplicate or triplicate wells. Bars show standard deviation. Variables with different letters are statistically different
(oneway ANOVA, p < 0.05)
Wijers et al. BMC Microbiology  (2016) 16:200 Page 4 of 10
and c). The infected HLCC monolayer in Ham’s F-12
complete medium showed no signs of damage either, al-
though clouds of bacterial cells were seen floating in the
supernatant (Fig. 4b). However, the HLCC monolayer in
60 % ASMDM infected with B. cenocepacia, showed
signs of damage as indicated by gaps in the HLCC
monolayer. Clouds of bacterial cells were observed as
well (Fig. 4d). An additional image file shows this in
more detail [see Additional file 1]. We think these
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Fig. 3 The effect of ASMDM on B. cenocepacia growth. B. cenocepacia was added to non-gas permeable 24-well plates containing ASMDM diluted
in Ham’s F-12 complete medium and incubated at 37 °C (7 % CO2). After 24 h, mean CFU/mL of B. cenocepacia in each well was compared to
the starting culture of B. cenocepacia (T0). There are statistically significant differences in mean CFU/mL ratio between 0 and 60–80 % (oneway
ANOVA, p = 0.03). Values are averages of four independent experiments with duplicate or triplicate wells. Bars show standard deviation. Variables
with different letters are statistically different (oneway ANOVA, p < 0.05)
a b
c d
Fig. 4 The effect of B. cenocepacia infection on the integrity of HLCC monolayers. Confluent HLCCs were subjected to Ham’s F-12 complete
medium (a and b) or 60 % ASMDM (c and d), infected with B. cenocepacia at MOI 0.3-5 (b and d) or mock-infected with saline (a and c), and
incubated at 37 °C (7 % CO2). After 24 h, HLCC monolayers were assessed for damage with an inverted Zeiss axiovert 40 CFL microscope (1000X
magnification). HLCC monolayers in both mock-infected wells are confluent with no damage (a and c). HLCC monolayer in Ham’s F-12 complete
medium with B. cenocepacia shows no sign of damage, although a dense mass is floating in the well. Because this is seen in infected wells only,
we think the aggregations are clouds of bacterial cells floating in the supernatant (arrows) (b). HLCC monolayer in 60 % ASMDM with B. cenocepacia
shows damage as indicated by gaps in the monolayer (black stars). Clouds of bacterial cells can be seen as well (arrows) (d)
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seen only in the infected wells. These observations indi-
cated that B. cenocepacia caused a breach in the integrity
of the established monolayer in the 60 % ASMDM.
We also examined the mean cell density and viability.
The mean cell density ratio significantly decreased in
mock-infected and infected HLCCs in 60 % ASMDM
compared to mock-infected HLCCs in Ham’s F-12
complete medium (Tukey-HSD post hoc, p = 0.0135 and
p = 0.0055, respectively) (Fig. 5). There was no significant
difference compared to the infected HLCCs in Ham’s F-
12 complete medium. However, the cell viability
dropped significantly in infected HLCCs grown in 60 %
ASMDM (Tukey-HSD post hoc, p < 0.0001) (Fig. 6).
These results indicated that 60 % ASMDM negatively af-
fected the cell density (Figs. 1 and 5), but the bacterial
infection negatively affected the cell viability.
To assess the ability of B. cenocepacia to grow in the
supernatant and inside the HLCC monolayer, the mean
ratio of bacterial CFU/mL was determined. The bacterial
levels were significantly high in the supernatants in all
infected wells, and no bacterial growth was observed in
any of the mock-infected wells (Fig. 7). A Tukey-HSD
post-hoc test indicated that the infected 60 % ASMDM
mean CFU/ml ratio is significantly higher than mock-
infected HLCCs in medium, mock-infected HLCCs in 60 %
ASMDM, mock-infected medium, and mock-infected
100 % ASMDM (Tukey-HSD post hoc, p = 0.0354 for all).
Bacteria were recovered from the monolayer from all
infected wells, but not from mock-infected wells (Fig. 8).
The bacterial CFU/mL ratio in infected HLCCs grown
in 60 % ASMDM was significantly greater than infected
and mock-infected HLCCs in medium, and in mock-
infected HLCCs in 60 % ASMDM (Tukey-HSD post
hoc, p = 0.0007, p = 0.0007, and p = 0.0013, respectively)
(Fig. 8). Collectively, B. cenocepacia grew well in the
supernatant and associated with the HLCC layer.
Discussion
Our goal was to develop an alternative, accessible model
that mimics the environment of CF airways and PCD–
another chronic airway disease–to investigate B. cenoce-
pacia infections. In order to establish this model, we first
needed to choose a cell line. CF epithelial cell lines are
not economically feasible, so we used the human lung
carcinoma A549 cell line (HLCCs). Next, we needed to
show that HLCCs could survive in ASMDM. The
ASMDM used in this study mimics the harsh conditions
in CF sputum that bacterial pathogens would encounter;
it is extremely viscous, acidic, and contains components
detected in CF sputum [14]. Initially, we exposed HLCCs
to 100 % ASMDM in regular tissue culture wells, but we
noted a substantial drop in both cell viability and density
(data not shown). We hypothesized the thick ASMDM
prevented appropriate cellular gas exchange so we grew
A A/B B B
Fig. 5 The effect of B. cenocepacia on HLCC density in 60 % ASMDM. Confluent HLCCs were exposed to 60 % ASMDM diluted in Ham’s F-12
complete medium, infected with B. cenocepacia at MOI 0.3-5 or mock-infected with saline, and incubated at 37 °C (7 % CO2). After 24 h, the cell
density (cells/mL) of each well was compared to the cell density of T24 control HLCCs. T24 control consisted of HLCCs in Ham’s F-12 complete
medium that were not manipulated (i.e. not washed, and medium not replaced) for the duration of the experiment. There are statistically significant
differences in mean cell density ratio between the different treatments (ANOVA, p = 0.0037). A Tukey-HSD post-hoc test indicated that the mean cell
density ratio in infected HLCCs + 60 % ASMDM is significantly different than in mock-infected HLCCs + Ham’s F-12 complete medium (p = 0.0055). The
mean cell density ratio in mock-infected HLCCs + 60 % ASMDM is significantly different than in mock-infected HLCCs + Ham’s F-12 complete medium
(p = 0.0135). Values are averages of three independent experiments with single wells. Bars show standard deviation. Variables with different letters are
statistically different (oneway ANOVA, p < 0.05)
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the HLCCs on gas permeable plates in 350 uL 100 %
ASMDM. Again, viability and density were very low with
a 100 % mortality. Instead, we tested a range of ASMDM
diluted in Ham’s complete medium in order to find an
appropriate balance of nutrients and gas exchange for
the cells. We chose the 60 % ASMDM because it was
the closest concentration that provided a healthy cell
viability. Interestingly, there was a drop (although not
statistically significant) in HLCC density in the presence
of ASMDM, but this decrease was not detected by visual
A A A B
Fig. 6 The effect of B. cenocepacia on HLCC viability in 60 % ASMDM. Confluent HLCCs were exposed to 60 % ASMDM diluted in Ham’s F-12
complete medium, infected with B. cenocepacia at MOI 5 or mock-infected with saline, and incubated at 37 °C (7 % CO2). After 24 h, HLCC viabil-
ity was determined using Trypan blue staining. There are statistically significant differences in mean cell viability between the different treatments
(ANOVA, p < 0.0001). A Tukey-HSD post-hoc test indicated that the mean cell viability of infected HLCCs + 60 % ASMDM is significantly different
than mock-infected HLCCs + Ham’s F-12 complete medium, infected HLCCs + Ham’s F-12 complete medium, and mock-infected HLCCs + 60 %
ASMDM (p < 0.0001 for all). Values are averages of three independent experiments with single wells. Bars show standard deviation. Variables with
different letters are statistically different (oneway ANOVA, p < 0.05)
A A A AB/C B/C B C
Fig. 7 The effect of 60 % ASMDM and HLCC monolayers on B. cenocepacia growth. Confluent HLCCs or wells without HLCCs were exposed to
60 % ASMDM diluted in Ham’s F-12 complete medium, infected with B. cenocepacia at MOI 5 or mock-infected with saline, and incubated at 37 °C
(7 % CO2). After 24 h, the bacterial density (CFU/mL) of each well was compared to the starting bacterial density (T0). There are statistically significant
differences in mean CFU/mL ratio between the different treatments (ANOVA, p = 0.0003). A Tukey-HSD post-hoc test showed the mean CFU/mL ratio
in infected 100 % ASMDM is significantly different than mock-infected HLCCs +medium, mock-infected HLCCs + 60 % ASMDM, infected or mock-in-
fected medium, and mock-infected 100 % ASMDM (p= 0.0024 for all). The mean CFU/mL ratio in infected HLCCs + 60 % ASMDM is significantly different
than mock-infected HLCCs +medium, mock-infected HLCCs + 60 % ASMDM, mock-infected medium, and mock-infected 100 % ASMDM (p= 0.0354).
Values are averages of three independent experiments with duplicate wells. Bars show standard deviation. Variables with different letters are statistically
different (oneway ANOVA, p< 0.05)
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inspection because the center of the monolayers were in-
tact. During the process of removing the ASMDM for
subsequent washes, we noted that some of the periphery
monolayer had detached. We think that the weight and
thickness of the ASMDM caused the detachment. An
additional image file shows this in more detail [see
Additional file 2]. These results indicate that the cells
survived ASMDM, but the ASMDM affected the ro-
bustness of the cell density.
Our second task was to show that B. cenocepacia could
grow in the ASMDM. Not only did B. cenocepacia grow
well, but the density increased over 100-fold in the pres-
ence of any ASMDM. The density increased the most
(nearly 1000-fold) in the gas permeable plates which is
understandable because these plates are designed to facili-
tate growth. These results align with the fact that Pseudo-
monas aeruginosa, another CF pathogen, is also able to
grow well in this artificial sputum medium [14].
Finally, we wanted to create a model that shows B.
cenocepacia damages the HLCCs. In the presence of
60 % ASMDM, B. cenocepacia associated with the
HLCC monolayer in large numbers, compared to
HLCCs in the presence of Ham’s F-12 complete medium
alone. Similar results were obtained by Sajjan et al. [16],
who found that B. cenocepacia was able to deeply invade
the cell layer of infected CF airway tissue samples in the
presence of a CF mucosal layer. However, B. cenocepacia
largely remained on the surface of the mucosal layer in
infected normal airway tissue samples in the presence of
a normal mucosal layer [16]. The fact that B. cenocepa-
cia associated with the cell layer in our model suggests
that HLCC monolayers in 60 % ASMDM approximates
the environment found in the CF airways, and that this
model may be a good starting point to study B. cenoce-
pacia infections in these airways.
Aside from the development of a new model to study
B. cenocepacia infections in CF and PCD airways, the
present study also indicates that CF sputum may play an
important role in the pathogenesis of B. cenocepacia.
Keeping in mind that ASMDM is similar to CF sputum,
there are two pieces of evidence that support this idea.
One, there was low viability of infected HLCCs in 60 %
ASMDM compared to infected HLCCs in Ham’s F-12
complete medium. Two, there was a large number of
bacterial cells found associated with the HLCC monolayers
in 60 % ASMDM compared to HLCC monolayers in Ham’s
F-12 complete medium. Collectively, these suggest that CF
sputum, unlike normal sputum, may enable B. cenocepacia
to reach and grow in or on the cell layers. In other words,
unlike normal sputum, which serves as a protective layer
against B. cenocepacia infection [16], CF sputum seems to
enhance the pathogenesis of B. cenocepacia.
One possible explanation for this phenomenon is that a
component of the ASMDM may activate B. cenocepacia
motility by inducing the expression of genes such as the
rpoN gene, which are required for motility [21], or flagellar
structural genes. Drevinek et al. [22], for example, demon-
strated that the expression of flagellar structural genes
A A A B
Fig. 8 The effect of 60 % ASMDM on the ability of B. cenocepacia to invade the HLCC monolayer. Confluent HLCCs were exposed to 60 %
ASMDM diluted in Ham’s F-12 complete medium, infected with B. cenocepacia at MOI 5 or mock-infected with saline, and incubated at 37 °C
(7 % CO2). After 24 h, HLCCs were washed and then lysed with sterile dH2O. The bacterial density (CFU/mL) in each lysate was compared to the
starting bacterial density at T0. Differences in mean ratio of CFU/mL were significantly different as indicated by oneway ANOVA (p = 0.0004). A
Tukey-HSD post-hoc test indicated that the mean ratio CFU/mL in infected HLCCs + 60 % ASMDM is significantly different than in infected or
mock-infected HLCCs +medium and in mock-infected HLCCs + 60 % ASMDM (p = 0.0007, p = 0.0007, and p = 0.0013, respectively). Values are averages
of three independent experiments with single wells. Bars show standard deviation. Variables with different letters are statistically different (oneway
ANOVA, p < 0.05)
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such as the fliF and fliS are upregulated in B. cenocepacia
when grown in CF sputum, indicating that CF sputum
properties may enhance B. cenocepacia motility [22]. CF
sputum may also affect B. cenocepacia motility by enhan-
cing its cepRI quorum sensing system, which controls cer-
tain motility genes [22, 23]. Moreover, previous studies
suggest that some B. cenocepacia quorum sensing genes
may be upregulated in CF sputum as well [22]. The signal
that leads to increased B. cenocepacia motility in ASMDM
may also originate from the eukaryotic host cells, rather
than from the sputum. Eukaryotic host cells secrete
certain signaling molecules in response to the inflamma-
tory stress induced by initial B. cenocepacia infection or
the presence of CF sputum. B. cenocepacia is known to
elicit the secretion of inflammatory signals such as IL-8 by
lung cells, for example [24, 25]. This signal may increase
B. cenocepacia motility in a manner similar to the one de-
scribed above, or it may even attract B. cenocepacia to the
eukaryotic cell layer by means of chemotaxis. In this study,
we found that the fold-increase in bacterial density is
greater in infected wells containing HLCCs in either 60 %
ASMDM or Ham’s F-12 complete medium than in infected
wells void of cells, although these differences were not sta-
tistically significant. This supports the notion that the
HLCCs could be releasing a signal detected by the bacteria.
Whether B. cenocepacia motility is increased randomly
or directionally towards the eukaryotic host cells by way
of chemotaxis, increased motility will likely lead to more
bacteria being associated with the host cell layer. Once it
reaches the host cell layer, B. cenocepacia could bind to
and cause damage to eukaryotic cell layers, which could
explain the decreased HLCC viability and degradation of
the infected monolayer observed in 60 % ASMDM.
Conclusion
The results of this study suggest that monolayers of
HLCCs in 60 % ASMDM grown in gas-permeable plates
serve as a viable starting point to investigate B. cenocepacia
infections in patients with CF and PCD. This model might
be used in the near future to further our understanding of
this particular pathogen, and to develop new ways to eradi-
cate this detrimental infection that, to this day, is still a sig-
nificant cause of morbidity and mortality in CF patients.
Additional files
Additional file 1: Bacterial clouds in F-12 medium and ASMDM wells.
Confluent HLCCs were subjected to Ham’s F-12 complete medium (A
and B) or 60 % ASMDM (C and D), infected with B. cenocepacia at MOI
0.3 (B and D) or mock-infected with saline (A and C), and incubated at
37 °C (7 % CO2). After 24 h, HLCC monolayers were assessed with an
inverted Zeiss axiovert 40 CFL microscope (1000X magnification), a
microscope-mounted camera, and Leica LAS v4.6.2. software. HLCC
monolayers in Ham’s F-12 complete medium and 60 % ASMDM with B.
cenocepacia show a dense mass in the upper left wells (arrows). Because
this is seen in infected wells only, we think these are clouds of bacterial
cells floating in the supernatant (B and D). Both mock-infected wells
show no clouds (A and C). (DOCX 679 kb)
Additional file 2: Detachment of cells with ASMDM exposure. HLCCs
were added to gas-permeable plates at 4 × 105 cells/mL. The plates were
incubated at 37 °C (7 % CO2) for 24 h to form a monolayer. The medium
was discarded, cells were washed once with 0.5 mL 1X HBSS, and then
exposed to either 0.5 mL Ham’s F-12 complete medium or 60 % ASMDM
suspended in Ham’s F-12 complete medium. Cells were mock-infected
with saline, and incubated at 37 °C (7 % CO2). After 24 h, the monolayer
was visualized at 400X magnification. The medium was discarded, cells
were washed in 0.5 mL 1X HBSS, and visualized again. The F-12 periphery
monolayer looks similar before (A) and after (B) the HBSS wash. In contrast,
the 60 % ASMDM shows cell detachment (arrows) before (C) the HBSS
wash, and there are larger, more noticeable gaps are seen after the wash
(D). (DOCX 1977 kb)
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